^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ARID1A mutation

    i
    Other names: ARID1A, AT-Rich Interaction Domain 1A, SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator Of Chromatin Subfamily F Member 1, AT-Rich Interactive Domain-Containing Protein 1A, AT Rich Interactive Domain 1A (SWI-Like), ARID Domain-Containing Protein 1A, SWI/SNF Complex Protein P270, BRG1-Associated Factor 250a, SWI-Like Protein, Osa Homolog 1, SMARCF1, C1orf4, BAF250, HOSA1, OSA1, AT Rich Interactive Domain 1A (SWI- Like), Chromatin Remodeling Factor P250, BRG1-Associated Factor 250, OS
    Entrez ID:
    8289
    Related biomarkers:
    Mutation
    CNA
    Others
    1year
    In an evaluation of patients with endometrioid ovarian carcinoma, ARID1A mutations occurred in 39% of patient samples, and PIK3CA mutations had an incidence rate of 38%. @DNasioudis @PennMedicine @SGO_org #gyncsm #SGOMtg https://t.co/ploujsZcIc (@OncLive)
    Clinical
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A)
    |
    PIK3CA mutation • ARID1A mutation
    1year
    https://t.co/niraqlDvi9 ARID1A is one of the most common driver mutations in gastric cancer, but has been hard to develop therapeutic strategies against. Here, using novel epigenetic sequencing methods, we show how this might now be possible. (@sundar__raghav)
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    over1year
    In @CellReports: A preclinical model of #cholangiocarcinoma that relies on ARID1A loss (in cooperation with mutant KRAS) induced disruption of TGFb/SMAD4 signaling pathway. https://t.co/mxm8Y8y0zc By Aram Hezel et al @UofR #OpenAccess (@Aiims1742)
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4)
    |
    KRAS mutation • ARID1A mutation • SMAD4 mutation
    almost2years
    .@BazzaroPhd and I are happy to have this article published today in @CRC_AACR, w/an unexpected biomarker finding: GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors https://t.co/jcNRTNIB6d (@cancerassassin1)
    Clinical
    |
    ARID1A (AT-rich interaction domain 1A) • GLS1 (Glutaminase)
    |
    ARID1A mutation
    almost2years
    p21/WAF1/CDKN1A truncating mutations exist in 8-10% of bladder cancers #eldeirylab CDKN1A/p21 WAF1, RB1, ARID1A, FLG, and HRNR mutation patterns provide insights into urinary tract environmental exposure carcinogenesis and potential treatment strategies https://t.co/dPwA9KYvOw (@weldeiry)
    RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • HRNR (Hornerin)
    |
    ARID1A mutation
    almost2years
    Curiouser and curiouser. I just learned the word "BRCAness" today from my virtual molecular tumor board results (via TRACK study) for #cholangiocarcinoma in re my #ARID1A mutation. Recommended pembrolizumab & olaparib upon recurrence. Just for interest... (@intraccsurvivor)
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    over2years
    ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion [Aug 7, 2019] @MikeRoyWilson et al. @NatureComms https://t.co/fVoy5QmsbO #openaccess #gyncsm #PrecisionMedicine (@mtmdphd)
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    over2years
    #bladdercancer monthly #research meeting @DanaFarber_GU-fantastic talk by @ClintonTim @BWHUrology on #Biology of #metastatic progression and potential role of ARID1A mutations in driving metastasis-?therapeutic implications @Varambally_S @ONealCancerUAB (@sonpavde)
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    over2years
    Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers | Cancer Research https://t.co/pwKigKR7ZW (@weldeiry)
    ARID1A (AT-rich interaction domain 1A) • ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1) • XBP1 (X-box-binding protein 1)
    |
    ARID1A mutation
    over2years
    Important data. ARID1A is frequently mutated in pancreas cancer but does not appear to respond to this ATR inhibitor (@PeterHoseinMD)
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    over2years
    Hi sir,kindly let me know the failed phase 3 trials of ovarian carcinoma. In clear cell ovarian carcinoma, immunotherapy works(ARID1A mutation).my sister (age 45)has recurrent metastatic ovarian clear cell carcinoma with overall survival of 2 years .so, kindly help. (@drvinoth2005)
    Clinical • P3 data • IO biomarker
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    over3years
    In the case of ovarian clear cell carcinoma with 50% ARID1A mutation, gemcitabine is an option (sorry, not included in your options). https://t.co/BIwuKBGF2g (@TakashiKohno2)
    Clinical
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    gemcitabine
    over3years
    Out in @CCR_AACR by @skopetz & team: ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable #crcsm @OncoAlert 🚨 #PrecisionMedicine https://t.co/G0j0O8B4XJ (@BenWestphalen)
    Clinical
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    over3years
    Wistar Scientists Discover Link Between a Genetic Driver of Ovarian Cancer and Metabolism, Opening the Way for New Therapeutic Strategies - ARID1A gene mutation https://t.co/iMUcsfDV4e @ronny_drapkin #gyncsm (@womenofteal)
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    over3years
    1/2 Need some #MedTwitter / @OncoAlert 🚨 swarm intelligence. Tomorrows molecular tumorboard, 57 y/o w metastatic #pancsm. Tumour profiling (including fusions) revealed a pathogenic ARID1A mutation. TMB 3. Patient is receiving FOLFIRINOX at the moment. #PrecisionMedicine (@BenWestphalen)
    Clinical
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    over3years
    Indeed this is a very important study in #kidneycancer !! It is interesting to see significant percentage of ARID1A/B mutations in RCC, which correlates with better efficacy with ICI+TKI. So much biology to learn! (@QingZhangLab)
    Clinical
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    almost4years
    NGS on primary/ met #breastca in 321 pts w/ BCBM @DanaFarber All subtypes represented. BCBMs were found most commonly to have mutations or copy # alterations in TP53, ERBB2, PIK3CA, GATA3, PTEN, ESR1, CDH1, BRCA2, ARID1A, BRCA1 (>5% freq) #asco20 #bcsm #btsm (@AshleySumrallMD)
    Clinical • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CDH1 (Cadherin 1) • GATA3 (GATA binding protein 3)
    |
    TP53 mutation • PIK3CA mutation • PTEN mutation • ARID1A mutation
    almost4years
    Next @LudaBazhenovaMD discusses 2 studies of biomarkers for IO. First, @drgandara presented data on the impact of ARID1A mutations on outcomes with IO. ARID1A deficiency is associated with high TMB and PD-L1 #ASCO20 #LCSM (@Jbauml)
    PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation